EZH2 and ovarian cancer: The HMT EZH2 modulates the tri-methylation of H3K27 to suppress the expression of the T helper1 (Th1)-type chemokines CXCL9 and CXCL10, which reduces the infiltration of effector T cells in ovarian cancer [32,41].